東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Promoting Brain Health through Identifying and Communicating Dementia Risk to Cognitively Unimpaired Older Adults.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Promoting Brain Health through Identifying and Communicating Dementia Risk to Cognitively Unimpaired Older Adults./
作者:	Erickson, Claire M.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2022,
面頁冊數:	174 p.
附註:	Source: Dissertations Abstracts International, Volume: 83-12, Section: B.
Contained By:	Dissertations Abstracts International83-12B.
標題:	Neurosciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29212267
ISBN:	9798819371381

Promoting Brain Health through Identifying and Communicating Dementia Risk to Cognitively Unimpaired Older Adults.
Erickson, Claire M.

Promoting Brain Health through Identifying and Communicating Dementia Risk to Cognitively Unimpaired Older Adults. - Ann Arbor : ProQuest Dissertations & Theses, 2022 - 174 p.

Source: Dissertations Abstracts International, Volume: 83-12, Section: B.

Thesis (Ph.D.)--The University of Wisconsin - Madison, 2022.

This item must not be sold to any third party vendors.

Alzheimer's disease (AD) is a neurodegenerative condition that in 2021 was affecting nearly 6.2 million Americans and cost $355 billion. These costs will continue to rise as demographic aging is expected to more than double the number of dementia cases in the US by 2050. AD is defined by the abnormal accumulation of beta-amyloid and tau protein aggregates, both of which can be detected in vivo using PET imaging and CSF assays years before clinical symptoms. Identifying people who are on the Alzheimer's disease tractor is crucial for early detection and intervention. It is estimated that 25% of healthy older adults have AD biomarkers and studies in cognitively unimpaired samples have demonstrated that having beta-amyloid is associated with subsequent cognitive decline. As the prognostic value of AD biomarkers is further elucidated, there is an increasing need to communicate the risk conferred by AD biomarkers to research participants and patients. Biomarker disclosure highlights the molecular basis of AD and amplifies its importance not only in research at the behavioral and clinical level, but also in policy at the individual and societal level. Sharing this information with individuals may lead to increased willingness to engage in health behaviors that may influence brain health and late-life planning that could impact the individual and institutional cost of aging. Currently, there are gaps in our understanding of the role of modifiable factors in AD course, best practices for AD biomarker disclosure, and the broader effects of biomarker disclosure on individuals and research studies. This work directly addresses such knowledge gaps in three aims designed to analyze how modifiable factors may impact cognitive trajectories (Aim 1); and then examine how such information can be effectively disclosed and utilized to promote health and mitigate AD risk. Aim 2 examines when and how to appropriately disclose biomarker status to cognitively unimpaired participants; and Aim 3 examines the effects of AD biomarker disclosure on research participants. Findings from this work may influence the development of interventions to delay the clinical manifestation of AD and contribute to the ongoing dialogue surrounding disclosure of personal disease-related information.

ISBN: 9798819371381Subjects--Topical Terms:

588700
Neurosciences.
Subjects--Index Terms:

Alzheimer's

Promoting Brain Health through Identifying and Communicating Dementia Risk to Cognitively Unimpaired Older Adults.
LDR:03454nmm a2200361 4500 001 2350948
005 20221028161058.5
008 241004s2022 ||||||||||||||||| ||eng d
020 $a 9798819371381
035 $a (MiAaPQ)AAI29212267
035 $a AAI29212267
040 $a MiAaPQ $c MiAaPQ
100 1 $a Erickson, Claire M. $3 3690486
245 1 0 $a Promoting Brain Health through Identifying and Communicating Dementia Risk to Cognitively Unimpaired Older Adults.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2022
300 $a 174 p.
500 $a Source: Dissertations Abstracts International, Volume: 83-12, Section: B.
500 $a Advisor: Johnson, Sterling C.
502 $a Thesis (Ph.D.)--The University of Wisconsin - Madison, 2022.
506 $a This item must not be sold to any third party vendors.
520 $a Alzheimer's disease (AD) is a neurodegenerative condition that in 2021 was affecting nearly 6.2 million Americans and cost $355 billion. These costs will continue to rise as demographic aging is expected to more than double the number of dementia cases in the US by 2050. AD is defined by the abnormal accumulation of beta-amyloid and tau protein aggregates, both of which can be detected in vivo using PET imaging and CSF assays years before clinical symptoms. Identifying people who are on the Alzheimer's disease tractor is crucial for early detection and intervention. It is estimated that 25% of healthy older adults have AD biomarkers and studies in cognitively unimpaired samples have demonstrated that having beta-amyloid is associated with subsequent cognitive decline. As the prognostic value of AD biomarkers is further elucidated, there is an increasing need to communicate the risk conferred by AD biomarkers to research participants and patients. Biomarker disclosure highlights the molecular basis of AD and amplifies its importance not only in research at the behavioral and clinical level, but also in policy at the individual and societal level. Sharing this information with individuals may lead to increased willingness to engage in health behaviors that may influence brain health and late-life planning that could impact the individual and institutional cost of aging. Currently, there are gaps in our understanding of the role of modifiable factors in AD course, best practices for AD biomarker disclosure, and the broader effects of biomarker disclosure on individuals and research studies. This work directly addresses such knowledge gaps in three aims designed to analyze how modifiable factors may impact cognitive trajectories (Aim 1); and then examine how such information can be effectively disclosed and utilized to promote health and mitigate AD risk. Aim 2 examines when and how to appropriately disclose biomarker status to cognitively unimpaired participants; and Aim 3 examines the effects of AD biomarker disclosure on research participants. Findings from this work may influence the development of interventions to delay the clinical manifestation of AD and contribute to the ongoing dialogue surrounding disclosure of personal disease-related information.
590 $a School code: 0262.
650 4 $a Neurosciences. $3 588700
650 4 $a Gerontology. $3 533633
650 4 $a Public health education. $3 2144801
653 $a Alzheimer's
653 $a Biomarkers
653 $a Disclosure
653 $a Policy
690 $a 0317
690 $a 0500
690 $a 0351
710 2 $a The University of Wisconsin - Madison. $b Neuroscience. $3 3188391
773 0 $t Dissertations Abstracts International $g 83-12B.
790 $a 0262
791 $a Ph.D.
792 $a 2022
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=29212267